N-(ARYLALKYL)-1H-INDOLE-2-SULFONIC ACID AMIDE COMPOUNDS AND THEIR THERAPEUTIC USE AS CANNABINOID ALLOSTERIC MODULATORS

Iain Robert Greig (Inventor), Ruth Alexandra Ross (Inventor), Laurent Alain Claude Trembleau (Inventor), Roger Guy Pertwee (Inventor), Mostafa H Abdelrahman (Inventor)

Research output: Patent

Abstract

The present invention pertains generally to the field of therapeutic compounds.
5 More specifically the present invention pertains to certain N-(arylalkyl)-1H-indole-
2-sulfonic acid amide compounds that, inter alia, inhibit cannabinoid receptor signalling.
The present invention also pertains to pharmaceutical compositions comprising such
compounds, and the use of such compounds and compositions, both in vitro and in vivo,
to inhibit cannabinoid receptor signalling; to treat disorders that are ameliorated by the
10 inhibition of cannabinoid receptor signalling; to treat metabolic syndrome, type-2 diabetes,
dyslipidaemia, obesity, eating disorders, cardiovascular diseases and disorders, and
other conditions as described herein
Original languageEnglish
Patent numberWO2012117216
IPCWO2012117216
Publication statusPublished - 28 Feb 2011

Fingerprint

Cannabinoid Receptors
Sulfonic Acids
Cannabinoids
Therapeutic Uses
Amides
Dyslipidemias
Type 2 Diabetes Mellitus
Cardiovascular Diseases
Obesity
Pharmaceutical Preparations
indole
Therapeutics

Cite this

@misc{df33474a2bf74c199a243eb38a9bfb5e,
title = "N-(ARYLALKYL)-1H-INDOLE-2-SULFONIC ACID AMIDE COMPOUNDS AND THEIR THERAPEUTIC USE AS CANNABINOID ALLOSTERIC MODULATORS",
abstract = "The present invention pertains generally to the field of therapeutic compounds. 5 More specifically the present invention pertains to certain N-(arylalkyl)-1H-indole- 2-sulfonic acid amide compounds that, inter alia, inhibit cannabinoid receptor signalling. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit cannabinoid receptor signalling; to treat disorders that are ameliorated by the 10 inhibition of cannabinoid receptor signalling; to treat metabolic syndrome, type-2 diabetes, dyslipidaemia, obesity, eating disorders, cardiovascular diseases and disorders, and other conditions as described herein",
author = "Greig, {Iain Robert} and Ross, {Ruth Alexandra} and Trembleau, {Laurent Alain Claude} and Pertwee, {Roger Guy} and Abdelrahman, {Mostafa H}",
year = "2011",
month = "2",
day = "28",
language = "English",
type = "Patent",
note = "WO2012117216; WO2012117216",

}

TY - PAT

T1 - N-(ARYLALKYL)-1H-INDOLE-2-SULFONIC ACID AMIDE COMPOUNDS AND THEIR THERAPEUTIC USE AS CANNABINOID ALLOSTERIC MODULATORS

AU - Greig, Iain Robert

AU - Ross, Ruth Alexandra

AU - Trembleau, Laurent Alain Claude

AU - Pertwee, Roger Guy

AU - Abdelrahman, Mostafa H

PY - 2011/2/28

Y1 - 2011/2/28

N2 - The present invention pertains generally to the field of therapeutic compounds. 5 More specifically the present invention pertains to certain N-(arylalkyl)-1H-indole- 2-sulfonic acid amide compounds that, inter alia, inhibit cannabinoid receptor signalling. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit cannabinoid receptor signalling; to treat disorders that are ameliorated by the 10 inhibition of cannabinoid receptor signalling; to treat metabolic syndrome, type-2 diabetes, dyslipidaemia, obesity, eating disorders, cardiovascular diseases and disorders, and other conditions as described herein

AB - The present invention pertains generally to the field of therapeutic compounds. 5 More specifically the present invention pertains to certain N-(arylalkyl)-1H-indole- 2-sulfonic acid amide compounds that, inter alia, inhibit cannabinoid receptor signalling. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit cannabinoid receptor signalling; to treat disorders that are ameliorated by the 10 inhibition of cannabinoid receptor signalling; to treat metabolic syndrome, type-2 diabetes, dyslipidaemia, obesity, eating disorders, cardiovascular diseases and disorders, and other conditions as described herein

M3 - Patent

M1 - WO2012117216

ER -